Press Releases

Date Title and Summary
Mar 11, 2022 Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®
CORAL GABLES, Fla. , March 11, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare
Mar 08, 2022 Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small Companies
The Company Ranked 65th of More Than 1,000 Companies Assessed CORAL GABLES, Fla. , March 08, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing
Mar 03, 2022 Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022
The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET CORAL GABLES, Fla. , March 03, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
Mar 02, 2022 Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio
Three New Patents Covering Additional Patient Amifampridine Metabolizer Types have been Allowed and will Issue in March 2022 Reinforces and Diversifies FIRDAPSE Long-Term Patent Portfolio Patent Portfolio Provides Intellectual Property Protection Until 2034 CORAL GABLES, Fla.
Feb 24, 2022 Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022
Ceremony Recognizes Importance of Biopharma Industry and Advocacy Group Collaboration to Address Needs for New Treatments in Orphan and Rare Disorders Together, Will Ring the Nasdaq Opening Bell to Kick-Off Rare Disease Day on February 28, 2022 CORAL GABLES, Fla. , Feb.
Feb 17, 2022 Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022
Initiative Part of Expansion of Education and Awareness Activities for Lambert-Eaton Myasthenic Syndrome Community CORAL GABLES, Fla. , Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused
Feb 07, 2022 Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate Update
2021 Total Revenues Estimated at $141 Million , Representing 18% YoY Growth Forecast 2022 Total Revenues of Between $195 Million and $205 Million , Representing YoY Growth of 38% to 45% Recently Regained Orphan Drug Exclusivity in the U.S. for Amifampridine to Treat LEMS Entering 2022 with a Strong
Feb 03, 2022 Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid
Earlier this Week the District Court Granted Summary Judgement to Catalyst in Its Lawsuit Against the FDA and this FDA Action is the Result of that Decision CORAL GABLES, Fla. , Feb. 03, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage,
Jan 28, 2022 Catalyst Pharmaceuticals Announces Issuance of Mandate by the U.S. Court of Appeals for the 11th Circuit Directing the District Court Judge in Catalyst's Lawsuit Against the FDA to Grant Summary Judgement in Favor of Catalyst
CORAL GABLES, Fla. , Jan. 28, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare
Jan 10, 2022 Catalyst Pharmaceuticals Announces 11th Circuit Court of Appeals Denial of Jacobus Pharmaceutical Company Inc.'s Petition for Rehearing
CORAL GABLES, Fla. , Jan. 10, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare

Displaying 11 - 20 of 21